EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An ex vivo functional biomarker of treatment response in pediatric low-grade glioma

Nichole M Artz, Breanna Mann iD, Aaron Ebbs, Rami Darawsheh, Rajaneekar Dasari, Adebimpe Adefolaju, Noah Bell, Dimitri Trembath iD, Dominique Higgins, Scott Elton, Albert Baldwin, Shawn Hingtgen und 2 weitere

PLOS One · 05.03.2026 · 21 (3) · e0331423

DOI: 10.1371/journal.pone.0331423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 05.03.2026. Verfasst von Nichole M Artz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United…. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Children with subtotally resected pediatric low-grade glioma (pLGG) often face multiple lines of treatment, which are seldom capable of eliminating the entire tumor. Genomics-based biomarkers are often used to select targeted therapies, but this paradigm only yields overall response rates of ~50%. Functional precision medicine (FPM), where patient-specific therapeutic efficacy is evaluated by directly treating individuals’ tumor outside their body, can predict individualized drug responses for some cancers, but pLGG is notoriously difficult to maintain outside the body, limiting development of FPM for pLGG. We describe the first platform that can maintain, treat, and analyze zero-passage pLGG tumor tissue ex vivo , facilitating FPM testing. Here, we tested pLGG tumors on our previously validated Screening Live Cancer Explants (SLiCE) platform, which allows engraftment and testing of diverse CNS tumor types atop organotypic brain slice cultures (OBSCs). After ensuring reproducible engraftment and maintenance of all three living pLGG tumor tissues on SLiCE, we measured MAPK pathway response to targeted therapies via immunoblotting. In the tested BRAF KIAA1549 fusion+ tumor, Western blot demonstrated maintenance of expected paradoxical MAPK upregulation in response to dabrafenib treatment. We then measured tumor response to targeted therapies on SLiCE. As expected, none of the BRAF KIAA1549 fusion+ pLGG tumors were sensitive to dabrafenib treatment. Two out of the three tumors demonstrated predicted sensitivity to trametinib, whereas one tumor did not. While no clinical correlates were measured in this proof-of-concept study, this mixed response to MEK inhibition on SLiCE is representative of heterogeneous real-world clinical responses. Together, these data demonstrate the feasibility of SLiCE to become a new functional biomarker of response in a tumor type where functional models are exceptionally rare, establishing a foundation for future individualized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBrain NeoplasmsBiomarkers, TumorHumansAnimalsChildOximesProto-Oncogene Proteins B-rafPyridonesPrecision MedicinePyrimidinonesImidazolesAntineoplastic AgentsTreatment OutcomeOncogene Proteins, Fusion

Substanzen

Biomarkers, TumorOximesdabrafenibProto-Oncogene Proteins B-raftrametinibPyridonesPyrimidinonesImidazolesBRAF-KIAA1549 fusion protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Eshelman Innovation, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Department of Neurosurgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

ORCID-Profile: Breanna Mann, Dimitri Trembath, Andrew B Satterlee

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Zitieren

APA

Artz, N. M., Mann, B., Ebbs, A., Darawsheh, R., Dasari, R., Adefolaju, A., Bell, N., Trembath, D., Higgins, D., Elton, S., Baldwin, A., Hingtgen, S., Kram, D. E., & Satterlee, A. B. (2026). An ex vivo functional biomarker of treatment response in pediatric low-grade glioma. PLOS One, 21(3), e0331423. https://doi.org/10.1371/journal.pone.0331423

Vancouver

Artz NM, Mann B, Ebbs A, Darawsheh R, Dasari R, Adefolaju A, et al. An ex vivo functional biomarker of treatment response in pediatric low-grade glioma. PLOS One. 2026;21(3):e0331423. doi:10.1371/journal.pone.0331423

BibTeX
@article{Artz2026,
  author = {Artz, Nichole M and Mann, Breanna and Ebbs, Aaron and Darawsheh, Rami and Dasari, Rajaneekar and Adefolaju, Adebimpe and Bell, Noah and Trembath, Dimitri and Higgins, Dominique and Elton, Scott and Baldwin, Albert and Hingtgen, Shawn and Kram, David E and Satterlee, Andrew B},
  title = {An ex vivo functional biomarker of treatment response in pediatric low-grade glioma},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {e0331423},
  doi = {10.1371/journal.pone.0331423}
}
Kostenlos starten →